PARTI OVERVIEW Mustang Bio,Inc. (Mustang, we, us, our or the Company) is a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs into potential cures for difficult-to-treat cancers. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. Our pipeline is currently focused on n...
Q2 FY2026 — expected 2026-07-07
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001104659-26-032063 | EDGAR | 78K words |
| 2025-03-28 | 2024-12-31 | 0001558370-25-003913 | EDGAR | — |
| 2024-03-11 | 2023-12-31 | 0001558370-24-002899 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001558370-23-004979 | EDGAR | — |
| 2022-03-23 | 2021-12-31 | 0001558370-22-004143 | EDGAR | — |
| 2021-03-24 | 2020-12-31 | 0001558370-21-003433 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001104659-20-034130 | EDGAR | — |
| 2019-03-18 | 2018-12-31 | 0001144204-19-014624 | EDGAR | — |
| 2018-03-29 | 2017-12-31 | 0001144204-18-017988 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0001144204-17-017831 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-07 | 2025-09-30 | 0001104659-25-108468 | EDGAR | 45K words |
| 2025-08-08 | 2025-06-30 | 0001558370-25-010920 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001558370-25-007736 | EDGAR | — |
| 2024-11-08 | 2024-09-30 | 0001558370-24-015048 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001558370-24-012051 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001558370-24-008283 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001558370-23-019010 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001558370-23-014832 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001558370-23-009592 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001558370-22-017819 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001558370-22-013261 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001558370-22-008525 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2025-12-23 | 0001104659-25-124189 | EDGAR | 1K words |
| 2025-07-09 | 0001104659-25-066520 | EDGAR | — |
| 2025-03-05 | 0001104659-25-020900 | EDGAR | — |
| 2025-02-27 | 0001104659-25-018299 | EDGAR | — |
| 2025-02-21 | 0001104659-25-016145 | EDGAR | — |
| 2025-02-13 | 0001104659-25-013029 | EDGAR | — |
| 2025-02-11 | 0001104659-25-011517 | EDGAR | — |
| 2025-01-17 | 0001104659-25-004565 | EDGAR | — |
| 2025-01-10 | 0001104659-25-002599 | EDGAR | — |
| 2025-01-02 | 0001104659-25-000343 | EDGAR | — |
190 total filings indexed. 158 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001680048 |
| Ticker | MBIO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.mustangbio.com |
| Listed | 2017-08-22 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report